

SYNTHESIS AND CHARACTERIZATION OF 1-(BENZOYL)-4-(ARYLIDENE)-3-METHYL-1H-PYRAZOL-5(4H)-ONES DERIVATIVES AND THEIR BIOLOGICAL ACTIVITIES

Hetal R. Makwana and Atul H. Makwana

Chemistry Department, St. Xavier's College (Autonomous),
(Affiliated to Gujarat University) Navarangpura, Ahmedabad-380009, India.

✉Corresponding authors: htmakwana@gmail.com

ABSTRACT

Pyrazole and its derivatives are considered pharmacologically active and it gives various types of biological activities. The presence of this nucleus in pharmacological agents of diverse therapeutic categories such as a potent anti-inflammatory, anti-microbial, and analgesic, has proved the pharmacological potential of the pyrazole moiety.

Keywords: Pyrazole Derivatives, Schiff Base, MIC-Bacillus Cereus MTCC 430, E.Coli MTCC 1687, Aspergillus Niger 16404.

RASAYAN J. Chem., Vol. 17, No. 4, 2024

INTRODUCTION

Pyrazoles are 5-membered rings and it is useful in various organic syntheses. Pyrazoles are one of the most studied groups of compounds among the azol¹ family. Pyrazole compound in different structures leads to various areas such as medicine, technology, and agriculture. Pyrazole compound give various type of biological activity reported over the years like anti-microbial², anti-tumor³, anti-depressant⁴, anti-fungal⁵⁻¹⁰ etc.




Fig.-1

EXPERIMENTAL

All chemicals used in the synthesis of the titled compounds were of analytical grade. The Melting points were reported by the open capillary tube method and are uncorrected. The reaction was monitored by thin-layer chromatography (TLC) and was carried out on Merck Kieselgel 60 F254 plates. IR spectra were recorded on the Shimadzu FT-IR 8400 using potassium bromide pellets. The ¹H NMR spectra were recorded in DMSO d₆ solution in 5 mm tubes at room temperature on a BRUKER 400 MHz FT-NMR with TMS (Tetramethyl silane) as an internal standard. Mass spectra were recorded on SHIMADZU QP-2010. The antimicrobial activity was carried out using the broth dilution method to determine the minimum inhibitory concentration (MIC).

Synthesis of Benzohydrazide (I)

Methyl benzoate (0.22 mol) with hydrazine hydrate (0.22 mol) in methanol at reflux for 7-8 hours. The reaction mixture was cooled, poured into crushed ice, and filtered. Product recrystallized from ethanol. It was filtered, washed with alcohol, and dried. The progress and completion of the reaction were confirmed by TLC. Mobile phase for TLC toluene: acetone (8:2), Yield: 75%, M.P.: 112-114 °C.

Synthesis of 1-(Benzoyl)-3-methyl-1H-pyrazol-5(4H)-one (II)

Benzohydrazide (0.01 mol) with ethyl acetoacetate (0.01 mol) in the presence of 20 ml of absolute ethanol, and a catalytic amount of triethylamine (1 ml) at reflux for 12 hours using a reflux condenser equipped with a magnetic stirrer. After the reaction was complete, the resultant reddish syrup was allowed

to cool to room temperature. It was washed thoroughly with ether to remove impurities. After the removal of the ether layer, The contents of the reaction mixture were then transferred to crushed ice to obtain precipitates 1-(Benzoyl)-3-methyl-1*H*-pyrazol-5(4*H*)-one. The solid products (II) formed were filtered, washed, and dried. Finally, the products were re-crystallized from alcohol. The progress and completion of the reaction were confirmed by TLC to yield.




Fig.-2: Reaction Scheme for the Synthesis of the Compounds III(a-n)

Synthesis of 1-(Benzoyl)-4-(arylidene)-3-methyl-1*H*-pyrazol-5(4*H*)-one (III).

1-(benzoyl)-3-methyl-1*H*-pyrazol-5(4*H*)-one (0.01 mol) with different aromatic aldehydes (0.01 mol) suspended in dry toluene was taken, and a presence of the catalytic amount of piperidine (0.5 ml) at reflux for 8–10 hours. The reaction contents were then poured into ice-cold water. The solid products (III) formed were filtered, washed, and dried. Finally, the products were re-crystallized from ethanol or methanol. The progress and completion of the reaction were confirmed by TLC to yield.

Table-1: Other Compounds of this III(a-n)) were Prepared by using the Same Method and their Physical Data were Recorded

S. No.	Compound Id	R	Molecular formula	M.W gm/mole	M.P.	% Yield	Elemental Analysis					
							% of Carbon		% of Nitrogen		% of Hydrogen	
							%Cal	% Obt.	%Cal	% Obt.	%Cal	% Obt.
1.	III _a	-H	C ₁₈ H ₁₄ N ₂ O ₂	290	282°C	75	74.47	74.58	9.65	9.75	4.86	4.87
2.	III _b	-3-NO ₂	C ₁₈ H ₁₃ N ₃ O ₄	335	265°C	65	64.47	64.58	12.53	12.55	3.91	3.94
3.	III _c	-4- Cl	C ₁₈ H ₁₃ N ₂ O ₂ Cl	325	235°C	70	66.57	66.58	8.63	8.95	4.03	4.04
4.	III _d	-4- OH	C ₁₈ H ₁₄ N ₂ O ₃	306	262°C	64	70.58	70.55	9.15	9.25	4.61	4.64
5.	III _e	-2-OH	C ₁₈ H ₁₄ N ₂ O ₃	306	250°C	73	70.58	70.56	9.15	9.27	4.61	4.65
6.	III _f	-4- OCH ₃	C ₁₉ H ₁₆ N ₂ O ₃	320	264°C	65	71.24	71.28	8.74	8.75	5.03	5.07
7.	III _g	-4-C ₈ H ₇	C ₂₀ H ₁₆ N ₂ O ₂	316	235°C	73	75.93	75.98	8.86	8.95	5.10	5.15
8.	III _h	-N(CH ₃) ₂	C ₂₀ H ₁₉ N ₃ O ₂	333	255°C	65	72.05	72.08	8.00	8.05	5.74	5.78
9.	III _i	-3,4,-(OCH ₃) ₂	C ₂₀ H ₁₆ N ₂ O ₂	376	239°C	78	68.56	68.58	12.60	12.68	5.18	5.20
10.	III _j	-2-Cl	C ₁₈ H ₁₃ N ₂ O ₂ Cl	325	268°C	56	66.57	66.58	8.63	8.65	4.03	4.05
11.	III _k	-2-NO ₂	C ₁₈ H ₁₃ N ₃ O ₄	335	248°C	74	64.47	64.58	12.53	12.55	3.91	3.93
12.	III _l	-3-OCH ₃ , 4-OH	C ₁₉ H ₁₆ N ₂ O ₄	336	285°C	56	67.85	67.58	8.33	8.35	4.79	4.78
13.	III _m	2,4-(OH) ₂	C ₁₈ H ₁₄ N ₂ O ₄	322	265°C	68	67.07	67.18	8.69	8.65	4.38	4.39
14.	III _n	-5-Br	C ₁₈ H ₁₃ N ₂ O ₂ Br	369	255°C	78	58.56	58.58	7.59	7.75	3.55	3.57

Spectral Data of Synthesized Compounds

1-Benzoyl-4-benzylidene-3-methyl-1*H*-pyrazol-5(4*H*)-one (III_a)

FTIR: (cm⁻¹, KBr): 1665(C=O stretching, Pyrazole ring), 1677(C=N stretching), 1685(C=O stretching, amide), 2935(C-H stretching in CH₃), DMSO, 400 MHz, ¹H NMR 2.5(3H, s, CH₃), 6.2(1H, s, CH), 6.5-

7.8(10H, m, aromatic ring), ^{13}C NMR: (DMSO, δ ppm): 111.11-124.45(Ar-C), 122.5(C=C), 142.8(C=N), 171.34(C=O), Elemental Analysis calculated: C-74.47%, H-4.86%, N-9.65%, Found: C-74.58%, H-4.87%, N-9.75%, MS(m/z): 290, Molecular formula: $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_2$.

1-Benzoyl-4-(3-nitrobenzylidene)-3-methyl-1H-pyrazol-5(4H)-one (III_b)

FTIR: (cm^{-1} , KBr): 1350(N=O stretching, aromatic NO_2), 1632(C=O stretching, pyrazole ring), 1667(C=N stretching), 1700(C=O stretching, amide), 2928(C-H stretching in CH_3), DMSO, 400 MHz, ^1H NMR: 3.3(3H, s, CH_3), 6.2(1H, s, CH), 6.8-7.9(9H, m, aromatic ring), ^{13}C NMR: (DMSO, δ ppm): 111.13-124.45(Ar-C), 120.5(C=C), 142.8(C=N), 171.44(C=O), Elemental Analysis Calculated: C-64.47%, H-3.91%, N-12.53%, Found: C-64.58%, H-3.94%, N-12.55%, MS (m/z): 335, Molecular formula: $\text{C}_{18}\text{H}_{13}\text{N}_3\text{O}_4$.

1-Benzoyl-3-methyl-4-(4-chlorobenzylidene)-1H-pyrazol-5(4H)-one (III_c)

FTIR: (cm^{-1} , KBr): 706 (C-Cl stretching), 1632(C=O stretching pyrazole ring), 1667(C=N stretching), 1708(C=O stretching, amide), 2936(C-H stretching in CH_3), DMSO, 400 MHz, ^1H NMR: 2.8(3H, s, CH_3), 5.6(1H, s, CH), 7.1-7.9(9H, m, aromatic ring), ^{13}C NMR: (DMSO, δ ppm): 111.11-129.49(Ar-C), 120.5(C=C), 142.8(C=N), 171.45(C=O), Elemental Analysis Calculated: C-66.57%, H-4.03%, N-8.63%, Found: C-66.58%, H-4.04%, N-8.95%, MS (m/z): 325, Molecular formula: $\text{C}_{18}\text{H}_{13}\text{ClN}_2\text{O}_2$.

1-Benzoyl--3-methyl-4-(4-hydroxybenzylidene)-1H-pyrazol-5(4H)-one (III_d)

FTIR: (cm^{-1} , KBr): 1635(C=O stretching), 1665(C=N stretching, pyrazole ring), 1685(C=O stretching, amide), 2955(C-H stretching in CH_3), 3015(O-H stretching), DMSO, 400 MHz, ^1H NMR: 2.3(3H, s, CH_3), 5.3(1H, s, OH), 6.2(1H, s, CH), 6.7-7.9(9H, m, aromatic ring), ^{13}C 54.55(-OCH₃), 82.05(C-OH), 112.11-125.45(Ar-C), 121.5(C=C), 141.8(C=N), 172.44(C=O), Elemental Analysis calculated: C-70.58%, H-4.61%, N-9.15%, Found: C 70.55%, H-4.64%, N-9.25%, MS (m/z): 306, Molecular formula: $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_3$.

1-Benzoyl-3-methyl-4-(2-hydroxybenzylidene)-1H-pyrazol-5(4H)-one (III_e)

FTIR: (cm^{-1} , KBr): 1635(C=O stretching, pyrazole ring), 1665(C=N stretching, pyrazole ring), 1689(C=O stretching, amide), 2945(C-H stretching in CH_3), 3026(O-H stretching), DMSO, 400 MHz, ^1H NMR: 2.3(3H, s, CH_3), 5.1(1H, s, OH), 6.1(1H, s, CH), 6.6-7.9(9H, m, aromatic ring), ^{13}C NMR: (DMSO, δ ppm): 82.05(C-OH), 112.11-125.45(Ar-C), 121.5(C=C), 141.8(C=N), 172.44(C=O), Elemental Analysis calculated: C-70.58%, H-4.61%, N-9.15%, Found: C-70.56%, H-4.65%, N-9.27%, MS (m/z): 306, Molecular formula: $\text{C}_{18}\text{H}_{14}\text{N}_2\text{O}_3$.

1-Benzoyl-3-methyl-4-(4-methoxybenzylidene)-1H-pyrazol-5(4H)-one (III_f)

IR: (cm^{-1} , KBr): 1632(C=O stretching, pyrazole ring), 1668(C=N stretching), 1701(C=O stretching, amide), 2837(-OCH₃), 2934(C-H stretching in CH_3), DMSO, 400 MHz, ^1H NMR: 2.2(3H, s, CH_3), 3.3(3H, s, OCH₃), 6.2(1H, s, CH), 6.5-7.9(9H, m, aromatic ring), ^{13}C NMR: (DMSO, δ ppm): 115.11-127.45(Ar-C), 122.5(C=C), 142.8(C=N), 171.54(C=O), Elemental Analysis Calculated: C-71.24%, H-5.03%, N-8.74%, Found: C-71.28%, H-5.07%, N-8.75%, MS(m/z): 320, Molecular formula: $\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}_3$.

1-Benzoyl-(3-methyl-4-phenylbut-en-1-ylidene)-1H-pyrazole-5(4H)-one (III_g)

IR: (cm^{-1} , KBr): 1603(C=N stretching), 1703(C=O stretching, pyrazole ring), 1723(C=O stretching, amide), 2975(C-H stretching in CH_3), ^1H NMR: (DMSO, 400 MHz) (δ ppm): 3.1(3H, s, CH_3), 6.3(1H, s, CH), 6.7-7.9(10H, m, aromatic ring), ^{13}C NMR: (DMSO, δ ppm): 110.21-132.45(Ar-C), 127.5(C=C), 143.8(C=N), 172.44(C=O), Elemental Analysis Calculated: C-75.93%, H-5.10%, N-8.86%, MS: (m/z): 316, Molecular formula: $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_2$, Found: C-75.98%, H-5.15%, N-8.95%.

1-Benzoyl-3-methyl-4-(4-dimethylaminobenzylidene)-1H-pyrazol-5(4H)-one (III_h)

IR: (cm^{-1} , KBr): 1665(C=N stretching), 1678(C=O stretching, pyrazole ring), 1704(C=O stretching, amide), 2931(C-H stretching in CH_3), DMSO, 400 MHz, ^1H NMR: 2.4(6H, s, NCH_3), 3.2(3H, s, CH_3), 6.1(1H, s, CH), 6.5-7.9 (8H, m, aromatic ring), ^{13}C NMR: (DMSO, δ ppm): 110.11-126.45(Ar-C),

123.5(C=C), 143.7(C=N), 171.54(C=O), Elemental Analysis Calculated: C-72.05%, H-5.74%, N-8.00%, Found: C-72.08%, H-5.78%, N-8.05%.

MS: (m/z): 333, Molecular formula: C₂₀H₁₉N₃O₂.

1-Benzoyl-3-methyl-4-(3,4-dimethoxybenzylidene)-1H-pyrazol-5(4H)-one (III_i)

IR: (cm⁻¹, KBr): 1663(C=N stretching), 1684(C=O stretching, pyrazole ring), 1702(C=O stretching, amide), 2831(-OCH₃ stretching), 2985(C-H stretching in CH₃).

DMSO, 400 MHz, ¹H NMR :2.2(3H, s, OCH₃), 3.1(3H, s, CH₃), 6.3(1H, s, CH), 6.5-7.9(9H, m, aromatic ring), ¹³C NMR: (DMSO, δ ppm):53.56(-OCH₃), 113.15-124.35(Ar-C), 125.5(C=C), 142.8(C=N), 171.44(C=O), Elemental Analysis Calculated: C-68.56%, H-5.18%, N-12.60%, Found: C-68.58%, H-5.20%, N-12.68%, MS (m/z): 376,

Molecular formula: C₂₀H₁₆N₂O₂.

1-Benzoyl-3-methyl-4-(2-chlorobenzylidene)-1H-pyrazol-5(4H)-one (III_j)

IR : (cm⁻¹, KBr): 745 (C-Cl stretching), 1665(C=N stretching), 1679(C=O stretching, pyrazole ring), 1704(C=O stretching, amide), 2955(C-H stretching in CH₃), DMSO, 400 MHz, ¹H NMR :2.2(3H, s, CH₃), 6.2(1H, s, CH), 6.4-7.9(9H, m, aromatic ring), ¹³C NMR (δ ppm, DMSO) 111.11-135.45(Ar-C), 120.5(C=C), 141.8(C=N), 172.44(C=O), , Elemental Analysis Calculated: C-66.57%, H-4.03%, N-8.63%, Found: C-66.58%, H-4.05%, N-8.65%, MS(m/z): 325, Molecular formula: C₁₈H₁₃N₂O₂Cl.

1-Benzoyl-3-methyl-4-(2-nitrobenzylidene)-1H-pyrazol-5(4H)-one (III_k)

IR: (cm⁻¹, KBr): 1535(N=O stretching, aromatic NO₂), 1632(C=O stretching, pyrazole ring), 1703(C=O stretching, amide), 1667(C=N stretching), 2929(C-H stretching in CH₃), DMSO, 400 MHz, ¹H NMR:3.3(3H, s, CH₃), 6.1(1H, s, CH), 6.7-8.7(9H, m, aromatic ring), ¹³C NMR: (DMSO, δ ppm): 124.11-134.45(Ar-C), 144.5(C=C), 147.8(C=N), 148.65 (C-NO₂), 171.44 (C=O), Elemental Analysis Calculated: C-64.58%, H-3.93%, N-12.55%, Found: C-64.58%, H-3.93%, N-12.55%, MS(m/z): 335,

Molecular formula: C₁₈H₁₃N₃O₄

1-Benzoyl-3-methyl-4-(3-methoxy-4-hydroxybenzylidene)-1H-pyrazol-5(4H)-one (III_l)

IR: (cm⁻¹, KBr): 1667(C=N stretching), 1654(C=O stretching, pyrazole ring), 1703(C=O stretching, amide), 2820(-OCH₃), 2956(C-H stretching in CH₃), 3066(O-H stretching).

DMSO, 400 MHz, ¹H NMR :2.3(3H, s, OCH₃), 3.3(3H, s, CH₃), 5.1(1H, s, OH), 6.1(1H, s, CH), 6.3-7.9(8H, m, aromatic ring), ¹³C NMR: (DMSO, δ ppm): 54.65(-OCH₃), 82.15(C-OH), 111.11-126.45(Ar-C), 121.5(C=C), 141.8(C=N), 172.44(C=O), Elemental Analysis Calculated: C-67.85%, H-4.79%, N-8.33%, Found: C-67.58%, H-4.78%, N-8.35%, MS(m/z): 336, Molecular formula: C₁₉H₁₆N₂O₄.

1-Benzoyl-3-methyl-4-(2,4-dihydroxybenzylidene)-1H-pyrazol-5(4H)-one (III_m)

FTIR: (cm⁻¹, KBr): 1665(C=N stretching), 1678(C=O stretching pyrazole ring), 1706(C=O stretching, amide), 2925(C-H stretching in CH₃), 3036(-O-H stretching), DMSO, 400 MHz, ¹H NMR, 2.4(3H, s, CH₃), 5.2(2H, s), 6.3(1H, s, CH), 6.3-7.9(8H, m, aromatic ring).

¹³C NMR: (DMSO, δ ppm): 81.05(C-OH), 113.11-128.45(Ar-C), 121.5(C=C), 142.8(C=N), 173.44(C=O), Elemental Analysis Calculated: C-67.07%, H-4.38%, N-8.69%,

Found: C-67.18%, H-4.39%, N-8.65%, MS(m/z): 322, Molecular formula: C₁₈H₁₄N₂O₄.

1-Benzoyl-3-methyl-4-(5-bromobenzylidene)-1H-pyrazol-5(4H)-one (III_n)

IR: (cm⁻¹, KBr): 565(C-Br stretching), 1667(C=N stretching), 1689(C=O stretching, pyrazole ring), 1705(C=O stretching, amide), 2915(C-H stretching in CH₃), DMSO, 400 MHz, ¹H NMR:2.4(3H, s, CH₃), 6.3(1H, s, CH), 6.5-7.9(9H, m, aromatic ring), ¹³C NMR: (DMSO, δ ppm):113.11-125.45(Ar-C), 122.5(C=C), 142.8(C=N), 173.44(C=O), Elemental Analysis Calculated: C-58.56%, H-3.55%, N-7.59%, Found: C-58.58%, H-3.57%, N-7.75%. MS(m/z): 369, Molecular formula: C₁₈H₁₃N₂O₂Br.

RESULTS AND DISCUSSION

In the present work, we have prepared a new series of pyrazole derivatives. The structures of newly synthesized compounds were confirmed by IR, ¹H NMR, and mass spectral analysis. Compound III_a showed strong stretching at 1665 cm⁻¹ due to the carbonyl group. Compound III_i showed strong

stretching at 1702cm^{-1} due to the carbonyl group and $\text{C}=\text{N}$ stretching at 1663cm^{-1} . All the synthesized compounds were screened for antibacterial and antifungal activities by broth dilution method. From the study of the biological activity data in reference to the standard drugs ampicillin and Amphotericin B, we found that compound III_l exhibited good activity against *S. aureus*, and compounds III_c, III_a, III_m, and III_k gave moderate activity against *S. aureus*.

CONCLUSION

In the present study, it was observed that the pyrazole moiety can be considered a promising pharmacophore for better antibacterial activities. It was found that varying the substitution in the final structure affected the biological activities. Final compounds with chloro, hydroxy, nitro, and methoxy were found to possess moderate antibacterial activity, and some of the compounds, for example, III_g, III_j, III_n moderate activity against *Aspergillus niger*.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the former Principal Fr. (Dr.) Robert Arockiasamy and Principal Fr. Lancelot D'cruze St. Xavier's College (Autonomous) (Affiliated to Gujarat University), Ahmedabad, for providing necessary laboratory and library facilities. The authors also wish to thank the staff of the Chemistry Department for their especially strong support and help during the course of the work.

CONFLICT OF INTERESTS

The authors declare that there is no conflict of interest regarding the publication of this article.

AUTHOR CONTRIBUTIONS

All the authors contributed significantly to this manuscript, participated in reviewing/editing and approved the final draft for publication. The research profile of the authors can be verified from their ORCID ids, given below:

Hetal Makwana  <https://orcid.org/0009-0003-5668-2151>

Atul Makwana  <https://orcid.org/0000-0002-5434-1156>

Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

1. T. Eicher, S. Hauptmann, A. Speicher, *Wiley-VCH*, **1**, (2003), <https://doi.org/10.1002/352760183X>
2. E. V. Pimerova, E. V. Voronina, *Pharmaceutical Chemistry Journal*, **35(11)**, 602(2001), <http://dx.doi.org/10.1023/A:1015141710100>
3. H. J. Park, L. Lee, S. Park, B. Ahn, J. C. Lee, H. Y. Cho, K. i. Lee, *Bioorganic and medicinal Chemistry Letters*, **15(13)**, 3307(2005), <https://doi.org/10.1016/j.bmcl.2005.03.082>
4. D. M. Bailey, P. E. Hansen, A. G. Hlavac, E. R. Baizman, J. Pearl, A. F. Defelice, M. A. Feigenson, *Journal of Medicinal Chemistry*, **28(2)**, 256(1985), <https://doi.org/10.1021/jm00380a020>
5. T. I. EL-Emary, A. Khalil, G. A. M. EL-hag Ali and A. A. A. M. EL-adasy, *Phosphorus, Sulfur, and Silicon and the Related Elements*, **180(1)**, 19(2005), <https://doi.org/10.1080/10426500490494778>
6. E. Akbas, I. Berber, A. Sener and B. hasanvov, *Elsevier Masson. IL Farmaco*, **60 (1)**, 23(2005), <https://doi.org/10.1016/j.farmac.2004.09.003>
7. A. Tanitame, Y. Oyamada, K. Ofuji, H. Tearauchi, M. Kawasaki, M. Wachi and J. Yamagishi, *Bioorganic & Medicinal Chemistry*, **12 (21)**, 5515(2004), <https://doi.org/10.1016/j.bmc.2004.08.010>
8. T. I. El-Emary, A. M. Kamal EL-Dean and H. S. El-kashef, *IL Farmaco*, **53(6)**, 383(1998), [https://doi.org/10.1016/S0014-827X\(98\)00014-7](https://doi.org/10.1016/S0014-827X(98)00014-7)
9. J. Sun, Y. Zhou, *Molecules*, **20(3)**, 4383(2015), <https://doi.org/10.3390/molecules20034383>
10. V. Rastija, K. Vrandecic, J. Cosic, K. S. Gabriella, I. Majic, D. Agic, D. Subaric, M. Karnas, D. Beslo, H. Brahmha, M. Komar, *International Journal of Molecular Science*, **24(11)**, 9335(2023), <https://doi.org/10.3390/ijms24119335>

[RJC- 8574/2024]